Tannheimer S L, Rehemtulla A, Ethier S P
Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
Breast Cancer Res. 2000;2(4):311-20. doi: 10.1186/bcr73. Epub 2000 May 24.
The fibroblast growth factor receptor (FGFR)2 gene has been shown to be amplified in 5-10% of breast cancer patients. A breast cancer cell line developed in our laboratory, SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2 message was found to be overexpressed 40-fold in SUM-52PE cells as compared with normal human mammary epithelial (HME) cells. Both human breast cancer (HBC) cell lines and HME cells expressed two FGFR2 isoforms, whereas SUM-52PE cells overexpressed those two isoforms, as well as several unique FGFR2 polypeptides. SUM-52PE cells expressed exclusively FGFR2-IIIb isoforms, which are high-affinity receptors for fibroblast growth factor (FGF)-1 and FGF-7. Differences were identified in the expression of the extracellular Ig-like domains, acid box and carboxyl termini, and several variants not previously reported were isolated from these cells.
成纤维细胞生长因子受体（FGFR）2基因在5%-10%的乳腺癌患者中被证实存在扩增。我们实验室培育的一种乳腺癌细胞系SUM-52PE，被证实FGFR2基因有12倍的扩增，并且与正常人乳腺上皮（HME）细胞相比，SUM-52PE细胞中FGFR2信息被发现有40倍的过表达。人乳腺癌（HBC）细胞系和HME细胞均表达两种FGFR2异构体，而SUM-52PE细胞过表达这两种异构体以及几种独特的FGFR2多肽。SUM-52PE细胞仅表达FGFR2-IIIb异构体，其是成纤维细胞生长因子（FGF）-1和FGF-7的高亲和力受体。在细胞外免疫球蛋白样结构域、酸性盒和羧基末端的表达中发现了差异，并且从这些细胞中分离出了几种以前未报道过的变体。
Zotero 插件
